Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Medical College of Wisconsin
Celgene
Takeda
Medical College of Wisconsin
H. Lee Moffitt Cancer Center and Research Institute
Medical College of Wisconsin
Pfizer
Takeda
Eli Lilly and Company
Celgene
Seagen Inc.
Seagen Inc.
National Heart, Lung, and Blood Institute (NHLBI)
Kyowa Kirin Co., Ltd.
Sierra Oncology LLC - a GSK company
National Heart, Lung, and Blood Institute (NHLBI)
Amgen
Takeda
NS Pharma, Inc.
National Heart, Lung, and Blood Institute (NHLBI)
Hoffmann-La Roche
Seagen Inc.
Takeda
CTI BioPharma
Novartis
University of Illinois at Chicago
Pfizer
Seagen Inc.
Merck Sharp & Dohme LLC
Novartis
Takeda
M.D. Anderson Cancer Center
CTI BioPharma
Gilead Sciences
National Heart, Lung, and Blood Institute (NHLBI)
Novartis
M.D. Anderson Cancer Center
Celgene
The Hospital for Sick Children
Fred Hutchinson Cancer Center
Novartis
Seagen Inc.
Seagen Inc.
Seagen Inc.
Children's Hospital of Michigan
M.D. Anderson Cancer Center
Sunesis Pharmaceuticals
Seagen Inc.
National Institutes of Health Clinical Center (CC)